Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | NOS1 | P29475 | 9/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59519 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL59520 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL30287655 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL13314521 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29776903 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29424531 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Xylitol SCHEMBL18285153 | 0.96 | HSD17B10 (0.68) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Mannitol SCHEMBL21903100 | 0.96 | HSD17B10 (0.68) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Phosphoric Acid SCHEMBL1443736 | 0.95 | HSD17B10 (0.63) | HSD17B10NOS1AKR1B1 | |
| SCHEMBL12559328 | 0.90 | HSD17B10 (0.66) | HSD17B10NOS1AKR1B1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-6562969-B1 | Ricin A-chain is an N-glycosidase that attacks ribosomal RNA at a highly conserved adenine residue. Crystallographic studies show that not only adenine and formycin, but also pterin-based rings can bind in the ricin active site. | RESEARCH DEVELOPMENT FOUNDATION | 2003-05-13 | — | — | US | disclosed |
| WO-2001073438-A1 | RICIN INHIBITORS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-10-04 | — | — | WO | disclosed |
| US-6177280-B1 | SCREENING FOR A RICIN INHIBITOR BY IDENTIFYING AND TESTING A COMPOUND WHICH BINDS TO THE ACTIVE SITE OF THE RICIN A CHAIN (RTA), HAS A MOLECULAR CORE RESEMBLING AN ADENINE MOIETY IN SIZE AND SHAPE AND IS DERIVATIZED WITH POLAR SUBSTITUENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-01-23 | — | — | US | disclosed |
| WO-1998028298-A1 | RICIN INHIBITORS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HSD17B10 1782/4885NOS1 1153/4885AKR1B1 1566/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HSD17B10 1782/4885NOS1 1153/4885AKR1B1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.